{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:58:36Z","timestamp":1791849516173,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sentinel lymph node biopsy (SLNB), the current gold standard for axillary staging for many breast cancer patients, has replaced axillary lymph node dissection (ALND) for clinically node-negative patients due to lower surgical morbidity while maintaining oncologic safety. Advances in breast cancer surgery, axillary staging, lymphatic mapping, targeted axillary dissection (TAD), neoadjuvant chemotherapy (NAC), and sentinel lymph node (SLN) identification techniques have reshaped axillary management and enabled progressive de-escalation of surgical treatment. This review examines the historical development, current clinical applications, and emerging innovations in SLNB. Early randomized trials including the NSABP B-32 and ALMANAC trials established SLNB as a safe alternative to ALND for clinically node-negative patients with comparable overall survival (OS), disease-free survival (DFS), and regional control while significantly reducing complications such as lymphedema. Subsequent trials including ACOSOG Z0011, IBCSG 23-01, and AMAROS further supported omission of completion ALND (cALND) for selected patients with limited SLN metastases. In the neoadjuvant setting, studies such as ACOSOG Z1071, SENTINA, and SN-FNAC evaluated SLNB accuracy after NAC and informed the development of optimized techniques, including dual-tracer mapping and TAD, to reduce false-negative rates. Technological advances including indocyanine green fluorescence imaging, technetium-99m radiotracers, and superparamagnetic iron oxide tracers have further improved SLN identification. Ongoing trials investigating SLNB omission and imaging-guided axillary staging continue to refine patient selection and advance the shift toward personalized, morbidity-conscious axillary management.<\/jats:p>","DOI":"10.1245\/s10434-026-19672-4","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:19:51Z","timestamp":1780060791000},"page":"8225-8237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Past, Present, and Future of Sentinel Lymph Node Biopsy in Breast Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Michael","family":"Stanczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-6124","authenticated-orcid":false,"given":"Julie E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"19672_CR1","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer. Version 2024. Retrieved 13 April 2024 at https:\/\/www.nccn.org."},{"key":"19672_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00000658-189407000-00075","volume":"20","author":"WS Halsted","year":"1894","unstructured":"Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. Ann Surg. 1894;20:497\u2013555.","journal-title":"Ann Surg."},{"key":"19672_CR3","first-page":"3863","volume":"40","author":"B Fisher","year":"1980","unstructured":"Fisher B. Laboratory and clinical research in breast cancer: a personal adventure: the David A. Karnofsky memorial lecture Cancer Res. 1980;40:3863\u201374.","journal-title":"Karnofsky memorial lecture. Cancer Res."},{"key":"19672_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJM198903303201302","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320:822\u20138.","journal-title":"N Engl J Med."},{"key":"19672_CR5","doi-asserted-by":"crossref","unstructured":"Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001;92:1368\u201377.","DOI":"10.1002\/1097-0142(20010915)92:6<1368::AID-CNCR1459>3.0.CO;2-9"},{"key":"19672_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.2008.17.9291","volume":"27","author":"SA Norman","year":"2009","unstructured":"Norman SA, Localio AR, Potashnik SL, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27:390\u20137.","journal-title":"J Clin Oncol."},{"key":"19672_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1097-0142(19940801)74:3<878::AID-CNCR2820740314>3.0.CO;2-4","volume":"74","author":"DE Wazer","year":"1994","unstructured":"Wazer DE, Erban JK, Robert NJ, et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer. 1994;74:878\u201383.","journal-title":"Cancer."},{"key":"19672_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9610(96)00249-8","volume":"172","author":"BJ Feigelson","year":"1996","unstructured":"Feigelson BJ, Acosta JA, Feigelson HS, Findley A, Saunders EL. T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection. Am J Surg. 1996;172:487\u201390.","journal-title":"Am J Surg."},{"key":"19672_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00000658-199309000-00013","volume":"218","author":"B Cady","year":"1993","unstructured":"Cady B, Stone MD, Wayne J. New therapeutic possibilities in primary invasive breast cancer. Ann Surg. 1993;218:338\u201349.","journal-title":"Ann Surg."},{"key":"19672_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/1097-0142(19940115)73:2<350::AID-CNCR2820730219>3.0.CO;2-5","volume":"73","author":"M Chadha","year":"1994","unstructured":"Chadha M, Chabon AB, Friedmann P, et al. Predictors of axillary lymph node metastases in patients with T1 breast cancer. Cancer. 1994;73:350\u20133.","journal-title":"Cancer."},{"key":"19672_CR11","first-page":"127","volume":"16","author":"U Veronesi","year":"1990","unstructured":"Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol. 1990;16:127\u201333.","journal-title":"Eur J Surg Oncol."},{"key":"19672_CR12","doi-asserted-by":"crossref","unstructured":"Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391\u20138.","DOI":"10.1097\/00000658-199409000-00015"},{"key":"19672_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546\u201353.","journal-title":"N Engl J Med."},{"key":"19672_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/cncr.21568","volume":"106","author":"T Kim","year":"2006","unstructured":"Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis. Cancer. 2006;106:4\u201316.","journal-title":"Cancer."},{"key":"19672_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1006\/jsre.1999.5629","volume":"84","author":"DM Miltenburg","year":"1999","unstructured":"Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res. 1999;84:138\u201342.","journal-title":"J Surg Res."},{"key":"19672_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138.","journal-title":"J Clin Oncol."},{"key":"19672_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.2001.19.3.602","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599\u2013609. https:\/\/doi.org\/10.1200\/JCO.2001.19.3.602. (PMID: 11157009).","journal-title":"J Natl Cancer Inst."},{"key":"19672_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927\u201333.","journal-title":"Lancet Oncol."},{"key":"19672_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21535","volume":"102","author":"T Ashikaga","year":"2010","unstructured":"Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111\u20138.","journal-title":"J Surg Oncol."},{"key":"19672_CR20","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918\u201326.","journal-title":"JAMA."},{"key":"19672_CR21","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1200\/JCO.2014.56.5838","volume":"32","author":"R Jagsi","year":"2014","unstructured":"Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol. 2014;32:3600\u20136.","journal-title":"J Clin Oncol."},{"key":"19672_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","volume":"20","author":"M Sol\u00e1","year":"2013","unstructured":"Sol\u00e1 M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000. Ann Surg Oncol. 2013;20:120\u20137.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR23","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455\u201361.","journal-title":"JAMA."},{"key":"19672_CR24","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1245\/s10434-022-12405-3","volume":"29","author":"G Montagna","year":"2022","unstructured":"Montagna G, Morrow M. ASO author reflections: do we need to clip metastatic lymph nodes at diagnosis and localize them after neoadjuvant chemotherapy? Ann Surg Oncol. 2022;29:6140\u20131.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609\u201318.","journal-title":"Lancet Oncol."},{"key":"19672_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258\u201364.","journal-title":"J Clin Oncol."},{"key":"19672_CR27","doi-asserted-by":"crossref","unstructured":"Tinterri C, Gentile D, Gatzemeier W, et al. Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial: C. Tinterri et al. Ann Surg Oncol. 2022;29:5732\u201344.","DOI":"10.1245\/s10434-022-11866-w"},{"key":"19672_CR28","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryd\u00e9n L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390:1163\u201375.","journal-title":"N Engl J Med."},{"key":"19672_CR29","doi-asserted-by":"crossref","unstructured":"Muslumanoglu M, Cabioglu N, Igci, et al. Combined analysis of the MF18\u201002\/MF18\u201003 NEOSENTITURK studies: ypN\u2010positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided. Cancer. 2025;131:e35610.","DOI":"10.1002\/cncr.35610"},{"key":"19672_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297\u2013305.","journal-title":"Lancet Oncol."},{"key":"19672_CR31","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310.","journal-title":"Lancet Oncol."},{"key":"19672_CR32","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.22.01565","volume":"41","author":"SA Bartels","year":"2023","unstructured":"Bartels SA, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS trial. J Clin Oncol. 2023;41:2159\u201365.","journal-title":"J Clin Oncol."},{"key":"19672_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"\u00c1 S\u00e1volt","year":"2017","unstructured":"S\u00e1volt \u00c1, P\u00e9ley G, Polg\u00e1r C, et al. Eight-year follow-up result of the OTOASOR trial: the optimal treatment of the axilla surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. EJSO Eur J Surg Oncol. 2017;43:672\u20139.","journal-title":"EJSO Eur J Surg Oncol."},{"key":"19672_CR34","doi-asserted-by":"crossref","unstructured":"Reimer T, Stachs A, Veselinovic K, et al. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): a randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2023;55:101765.","DOI":"10.1016\/j.eclinm.2022.101756"},{"key":"19672_CR35","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1200\/JCO-25-00099","volume":"43","author":"KU Park","year":"2025","unstructured":"Park KU, Somerfield MR, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025;43:1720\u201341.","journal-title":"J Clin Oncol."},{"key":"19672_CR36","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023;9:1557\u201364.","journal-title":"JAMA Oncol."},{"key":"19672_CR37","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1200\/JCO.24.01052","volume":"43","author":"G Montagna","year":"2025","unstructured":"Montagna G, Laws A, Ferrucci M, et al. Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study. J Clin Oncol. 2025;43:810\u201320.","journal-title":"J Clin Oncol."},{"key":"19672_CR38","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","volume":"392","author":"EP Mamounas","year":"2025","unstructured":"Mamounas EP, Bandos H, White JR, et al. Omitting regional nodal irradiation after response to neoadjuvant chemotherapy. N Engl J Med. 2025;392:2113\u201324.","journal-title":"N Engl J Med."},{"key":"19672_CR39","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.20892\/j.issn.2095-3941.2022.0085","volume":"19","author":"J Li","year":"2022","unstructured":"Li J, Cheng J, Liu G, et al. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial. Cancer Biol Med. 2022;19:1100\u20138.","journal-title":"Cancer Biol Med."},{"key":"19672_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1072-7515(98)00060-X","volume":"186","author":"BJ O\u2019Hea","year":"1998","unstructured":"O\u2019Hea BJ, El-Shirbiny AM, Yeh SD, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998;186:423\u20137.","journal-title":"J Am Coll Surg."},{"key":"19672_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.amjsurg.2004.06.042","volume":"189","author":"S Thevarajah","year":"2005","unstructured":"Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg. 2005;189:236\u20139.","journal-title":"Am J Surg."},{"key":"19672_CR42","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/cncr.21226","volume":"104","author":"CP Raut","year":"2005","unstructured":"Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005;104:692\u20139.","journal-title":"Cancer."},{"issue":"3","key":"19672_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1245\/ASO.2003.04.021","volume":"10","author":"R Simmons","year":"2003","unstructured":"Simmons R, Thevarajah S, Brennan MB, Christos P, Osborne M. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol. 2003;10(3):242\u20137.","journal-title":"Ann Surg Oncol"},{"key":"19672_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0002-9610(02)00948-0","volume":"184","author":"WD Blessing","year":"2002","unstructured":"Blessing WD, Stolier AJ, Teng SC, Bolton JS, Fuhrman GM. A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping. Am J Surg. 2002;184:341\u20135.","journal-title":"Am J Surg."},{"key":"19672_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0748-7983(98)92827-X","volume":"24","author":"M Koller","year":"1998","unstructured":"Koller M, Barsuk D, Zippel DE, Engelberg S, Ben-Ari G, Papa MZ. Sentinel lymph node involvement: a predictor for axillary node status with breast cancer: has the time come? EJSO Eur J Surg Oncol. 1998;24:166\u20138.","journal-title":"EJSO Eur J Surg Oncol."},{"key":"19672_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7150\/jca.2.20","volume":"2","author":"FJ Reyes","year":"2010","unstructured":"Reyes FJ, Noelck MB, Valentino C, Grasso-Lebeau L, Lang JE. Complications of methylene blue dye in breast surgery: case reports and review of the literature. J Cancer. 2010;2:20.","journal-title":"J Cancer."},{"key":"19672_CR47","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jjco\/29.12.604","volume":"29","author":"K Motomura","year":"1999","unstructured":"Motomura K, Inaji H, Komoike Y, Kasugai T, Noguchi S, Koyama H. Sentinel node biopsy guided by indocyanin green dye in breast cancer patients. Japan J Clin Oncol. 1999;29:604\u20137.","journal-title":"Japan J Clin Oncol."},{"key":"19672_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2325\/jbcs.12.211","volume":"12","author":"T Kitai","year":"2005","unstructured":"Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211\u20135.","journal-title":"Breast Cancer."},{"key":"19672_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155597","volume":"11","author":"X Zhang","year":"2016","unstructured":"Zhang X, Li Y, Zhou Y, et al. Diagnostic performance of indocyanine green-guided sentinel lymph node biopsy in breast cancer: a meta-analysis. PLoS One. 2016;11:e0155597.","journal-title":"PLoS One."},{"key":"19672_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10147-016-1064-z","volume":"22","author":"T Sugie","year":"2017","unstructured":"Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol. 2017;22:11\u20137.","journal-title":"Int J Clin Oncol."},{"key":"19672_CR51","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/1553350613503737","volume":"21","author":"D Murawa","year":"2014","unstructured":"Murawa D, Polom K, Murawa P. One-year postoperative morbidity associated with near-infrared\u2013guided indocyanine green (ICG) or ICG in conjugation with human serum albumin (ICG: HSA) sentinel lymph node biopsy. Surg Innovation. 2014;21:240\u20133.","journal-title":"Surg Innovation."},{"key":"19672_CR52","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.amjsurg.2007.02.032","volume":"195","author":"N Tagaya","year":"2008","unstructured":"Tagaya N, Yamazaki R, Nakagawa A, et al. Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer. Am J Surg. 2008;195:850\u20133.","journal-title":"Am J Surg."},{"key":"19672_CR53","first-page":"5924802","volume":"2017","author":"J Berrocal","year":"2017","unstructured":"Berrocal J, Saperstein L, Grube B, et al. Intraoperative injection of technetium-99m sulfur colloid for sentinel lymph node biopsy in breast cancer patients: a single-institution experience. Surg Res Pract. 2017;2017:5924802.","journal-title":"Surg Res Pract."},{"key":"19672_CR54","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10585-012-9497-x","volume":"29","author":"CA Tokin","year":"2012","unstructured":"Tokin CA, Cope FO, Metz WL, et al. The efficacy of tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the 99m Tc-labeled nanocolloid human serum albumin standard of care. Clin Exper Metastasis. 2012;29:681\u20136.","journal-title":"Clin Exper Metastasis."},{"key":"19672_CR55","first-page":"1198","volume":"42","author":"G Mariani","year":"2001","unstructured":"Mariani G, Moresco L, Viale G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med. 2001;42:1198\u2013215.","journal-title":"J Nucl Med."},{"key":"19672_CR56","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1245\/s10434-015-4802-y","volume":"22","author":"JT Unkart","year":"2015","unstructured":"Unkart JT, Baker JL, Hosseini A, et al. Comparison of post-injection-site pain between technetium sulfur colloid and technetium tilmanocept in breast cancer patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2015;22:559\u201365.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR57","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00268-012-1623-z","volume":"36","author":"S Pesek","year":"2012","unstructured":"Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg. 2012;36:2239\u201351.","journal-title":"World J Surg."},{"key":"19672_CR58","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307\u201316.","journal-title":"N Engl J Med."},{"key":"19672_CR59","unstructured":"Wong SL, Harris JR, Hughes KS, et al. Society of surgical oncology choosing wisely committee. Don\u2019t routinely use sentinel node biopsy in clinically node-negative women aged 70 years or older with early-stage hormone receptor-positive, HER2-negative breast cancer. In: Choosing wisely: An initiative of the ABIM foundation; 2016. https:\/\/www.choosingwisely.org."},{"key":"19672_CR60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamasurg.2015.0647","volume":"150","author":"A Chung","year":"2015","unstructured":"Chung A, Gangi A, Amersi F, Zhang X, Giuliano A. Not performing a sentinel node biopsy for older patients with early-stage invasive breast cancer. JAMA Surg. 2015;150:683\u20134.","journal-title":"JAMA Surg."},{"key":"19672_CR61","doi-asserted-by":"crossref","first-page":"A55","DOI":"10.1016\/j.jamcollsurg.2006.06.009","volume":"203","author":"CM Rudenstam","year":"2006","unstructured":"Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10\u201393. J Am Coll Surg. 2006;203:A55.","journal-title":"J Am Coll Surg."},{"key":"19672_CR62","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1245\/s10434-023-13886-6","volume":"30","author":"NH Goldhaber","year":"2023","unstructured":"Goldhaber NH, O\u2019Keefe T, Kang J, Douglas S, Blair SL. Is choosing wisely wise for lobular carcinoma in patients over 70 years of age? A National Cancer Database analysis of sentinel node practice patterns. Ann Surg Oncol. 2023;30:6024\u201332.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.17129","volume":"3","author":"T Wang","year":"2020","unstructured":"Wang T, Mott N, Miller J, et al. Patient perspectives on treatment options for older women with hormone receptor-positive breast cancer: a qualitative study. JAMA Netwk Open. 2020;3:e2017129.","journal-title":"JAMA Netwk Open."},{"key":"19672_CR64","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28524","volume":"5","author":"CA Minami","year":"2022","unstructured":"Minami CA, Bryan AF, Freedman RA, et al. Assessment of oncologists\u2019 perspectives on omission of sentinel lymph node biopsy in women 70 years and older with early-stage hormone receptor-positive breast cancer. JAMA Netwk Open. 2022;5:e2228524.","journal-title":"JAMA Netwk Open."},{"key":"19672_CR65","doi-asserted-by":"crossref","unstructured":"Derossis AM, Fey JV, Cody III HS, Borgen PI. Obesity influences outcome of sentinel lymph node biopsy in early-stage breast cancer. J Am Coll Surg. 2003;197:896\u2013901.2228524.","DOI":"10.1016\/j.jamcollsurg.2003.08.005"},{"key":"19672_CR66","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1148\/radiology.180.1.2052688","volume":"180","author":"RS Werner","year":"1991","unstructured":"Werner RS, McCormick B, Petrek J, et al. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology. 1991;180:177\u201384.","journal-title":"Radiology."},{"key":"19672_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-019-1367-0","volume":"14","author":"A Sato","year":"2019","unstructured":"Sato A, Sakai T, Iwase T, et al. Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence. Radiat Oncol. 2019;14:1\u20137.","journal-title":"Radiat Oncol."},{"key":"19672_CR68","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejso.2011.10.003","volume":"38","author":"MS Kothari","year":"2012","unstructured":"Kothari MS, Rusby JE, Agusti AA, MacNeill FA. Sentinel lymph node biopsy after previous axillary surgery: a review. EJSO Eur J Surg Oncol. 2012;38:8\u201315.","journal-title":"EJSO Eur J Surg Oncol."},{"key":"19672_CR69","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1245\/s10434-018-6358-0","volume":"25","author":"IG Poodt","year":"2018","unstructured":"Poodt IG, Vugts G, Schipper RJ, Nieuwenhuijzen GA. Repeat sentinel lymph node biopsy for ipsilateral breast tumor recurrence: a systematic review of the results and impact on prognosis. Ann Surg Oncol. 2018;25:1329\u201339.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR70","doi-asserted-by":"crossref","unstructured":"Ikeda T. Re-sentinel node biopsy after previous breast and axillary surgery. Surg Today. 2014;44:2015\u201321.35610.","DOI":"10.1007\/s00595-013-0783-2"},{"key":"19672_CR71","doi-asserted-by":"crossref","unstructured":"Goyal A, Newcombe RG, Chhabra A, Mansel RE, ALMANAC Trialists Group. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer: results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203\u20138.","DOI":"10.1007\/s10549-006-9192-1"},{"key":"19672_CR72","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/cancers13071539","volume":"13","author":"PK Swarnkar","year":"2021","unstructured":"Swarnkar PK, Tayeh S, Michell MJ, Mokbel K. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers. 2021;13:1539.","journal-title":"Cancers."},{"key":"19672_CR73","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3390\/diagnostics14111175","volume":"14","author":"M Alamoodi","year":"2024","unstructured":"Alamoodi M, Wazir U, Venkataraman J, Almukbel R, Mokbel K. Assessing the efficacy of radioactive iodine seed localisation in targeted axillary dissection for node-positive early breast cancer patients undergoing neoadjuvant systemic therapy: a systematic review and pooled analysis. Diagnostics. 2024;14:1175.","journal-title":"Diagnostics."},{"key":"19672_CR74","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/cancers16071345","volume":"16","author":"U Wazir","year":"2024","unstructured":"Wazir U, Michell MJ, Alamoodi M, Mokbel K. Evaluating radar reflector localisation in targeted axillary dissection in patients undergoing neoadjuvant systemic therapy for node-positive early breast cancer: a systematic review and pooled analysis. Cancers. 2024;16:1345.","journal-title":"Cancers."},{"key":"19672_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cson.2024.100051","volume":"3","author":"KT Subramanian","year":"2024","unstructured":"Subramanian KT, Elnour A, Kurup V. Comparison of three new wireless non-radiation techniques for localisation of non-palpable breast cancer-an updated systematic review and pooled meta-analysis. Clin Surg Oncol. 2024;3:100051.","journal-title":"Clin Surg Oncol."},{"key":"19672_CR76","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1245\/s10434-023-13252-6","volume":"30","author":"V Man","year":"2023","unstructured":"Man V, Suen D, Kwong A. Use of superparamagnetic iron oxide (SPIO) versus conventional technique in sentinel lymph node detection for breast cancer: a randomised controlled trial. Ann Surg Oncol. 2023;30:3237\u201344.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR77","unstructured":"U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED): Magtrace\u00ae and Sentimag\u00ae magnetic localization system. Premarket approval application (PMA) P160053\/S002 [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2022. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/P160053S002B.pdf"},{"key":"19672_CR78","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/ans.18936","volume":"94","author":"RB Cui","year":"2024","unstructured":"Cui RB, Hawes S, Azimi F, et al. Avoiding unnecessary sentinel lymph node biopsy with the use of superparamagnetic iron oxide mapping agents (Magtrace) in breast surgery. ANZ J Surg. 2024;94:1090\u20135.","journal-title":"ANZ J Surg."},{"key":"19672_CR79","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1245\/s10434-022-13064-0","volume":"30","author":"A Karakatsanis","year":"2023","unstructured":"Karakatsanis A, Eriksson S, Pistiolis L, et al. Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: the SentiNot study. Ann Surg Oncol. 2023;30:4064\u201372.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR80","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","volume":"14","author":"T DiSipio","year":"2013","unstructured":"DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500\u201315.","journal-title":"Lancet Oncol."},{"key":"19672_CR81","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1055\/s-0044-1785680","volume":"40","author":"MC M\u00e9dor","year":"2024","unstructured":"M\u00e9dor MC, Churchill IF, Pereira D, et al. Lymphovenous bypass for immediate lymphatic reconstruction in breast cancer patients undergoing axillary lymph node dissection: minimizing the risk of upper extremity lymphedema. J Reconstr Microsurg. 2024;40:713\u201321.","journal-title":"J Reconstr Microsurg."},{"key":"19672_CR82","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/micr.22254","volume":"34","author":"F Boccardo","year":"2014","unstructured":"Boccardo F, Casabona F, DeCian F, et al. Lymphatic microsurgical preventing healing approach (LYMPHA) for primary surgical prevention of breast cancer-related lymphedema: over 4 years follow-up. Microsurgery. 2014;34:421\u20134.","journal-title":"Microsurgery."},{"key":"19672_CR83","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10549-025-07867-4","volume":"215","author":"S Brown","year":"2026","unstructured":"Brown S, Shen Y, Klimitz FJ, et al. Lymphovenous bypass for the treatment of secondary lymphedema: a meta-analysis of prospective outcomes. Breast Cancer Res Treat. 2026;215:42.","journal-title":"Breast Cancer Res Treat."},{"key":"19672_CR84","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/BF02574496","volume":"9","author":"KK Swenson","year":"2002","unstructured":"Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol. 2002;9:745\u201353.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR85","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/sj.bjc.6601150","volume":"89","author":"F Peintinger","year":"2003","unstructured":"Peintinger F, Reitsamer R, Stranzl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003;89:648\u201352.","journal-title":"Br J Cancer."},{"key":"19672_CR86","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.breast.2018.08.105","volume":"42","author":"K Wang","year":"2018","unstructured":"Wang K, Yee C, Tam S, et al. Prevalence of pain in patients with breast cancer post-treatment: a systematic review. Breast. 2018;42:113\u201327.","journal-title":"Breast."},{"key":"19672_CR87","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/08941939.2019.1684603","volume":"34","author":"S Tokg\u00f6z","year":"2021","unstructured":"Tokg\u00f6z S, Karaca Umay E, Yilmaz KB, et al. Role of intraoperative nerve monitoring in postoperative muscle and nerve function of patients undergoing modified radical mastectomy. J Invest Surg. 2021;34:703\u201310.","journal-title":"J Invest Surg."},{"key":"19672_CR88","unstructured":"Alliance for Clinical Trials in Oncology, National Cancer Institute, Canadian Cancer Trials Group. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy. ClinicalTrials.gov; 2014. https:\/\/classic.clinicaltrials.gov\/show\/NCT01901094"},{"key":"19672_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-018-3021-9","volume":"19","author":"G Henke","year":"2018","unstructured":"Henke G, Knauer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018;19:1\u201328.","journal-title":"Trials."},{"key":"19672_CR90","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1245\/s10434-014-3752-0","volume":"21","author":"J Gooch","year":"2014","unstructured":"Gooch J, King TA, Eaton A, Dengel L, Stempel M, Corben AD, Morrow M. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1\u2013T2 breast cancer. Ann Surg Oncol. 2014;21:2897\u2013903.","journal-title":"Ann Surg Oncol."},{"key":"19672_CR91","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.3390\/cancers12123698","volume":"12","author":"T Reimer","year":"2020","unstructured":"Reimer T, Glass A, Botteri E, Loibl S, Gentilini O. Avoiding axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: rationale for the prospective, multicentric EUBREAST-01 trial. Cancers. 2020;12:3698.","journal-title":"Cancers."},{"key":"19672_CR92","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4048\/jbc.2023.0264","volume":"27","author":"JM Ryu","year":"2024","unstructured":"Ryu JM, Lee H, Han W, et al. Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in human epidermal growth factor 2-positive\/triple-negative breast cancer patients with excellent response. J Breast Cancer. 2024;27:130\u201353.","journal-title":"J Breast Cancer."},{"issue":"9 Suppl","key":"19672_CR93","first-page":"PS01","volume":"84","author":"JM Ryu","year":"2024","unstructured":"Ryu JM, Lee HB, Ahn SH, et al. Abstract PS01-03: what to expect from the no axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS] trial (KBCSG-21): clinicopathologic characteristics and axillary lymph node status of enrolled patients. Cancer Res. 2024;84(9 Suppl):PS01-03.","journal-title":"Cancer Res."},{"key":"19672_CR94","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers13071565","volume":"13","author":"M Banys-Paluchowski","year":"2021","unstructured":"Banys-Paluchowski M, Gasparri ML, de Boniface J, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers. 2021;13:1565.","journal-title":"Cancers."},{"key":"19672_CR95","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/a-1889-7883","volume":"82","author":"S Hartmann","year":"2022","unstructured":"Hartmann S, K\u00fchn T, Hauptmann M, et al. Axillary staging after neoadjuvant chemotherapy for initially node-positive breast carcinoma in Germany. Geburtshilfe Frauenheilkunde. 2022;82:932\u201340.","journal-title":"Geburtshilfe Frauenheilkunde."},{"key":"19672_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054365","volume":"11","author":"A Goyal","year":"2021","unstructured":"Goyal A, Mann GB, Fallowfield L, Whitham D, et al. POSNOC\u2013POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open. 2021;11:e054365.","journal-title":"BMJ Open."},{"key":"19672_CR97","doi-asserted-by":"publisher","first-page":"1184021","DOI":"10.3389\/fonc.2023.1184021","volume":"13","author":"A Garcia-Tejedor","year":"2023","unstructured":"Garcia-Tejedor A, Ortega-Exposito C, Salinas S, et al. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Front Oncol. 2023;13:1184021.","journal-title":"Front Oncol."},{"issue":"4 Suppl","key":"19672_CR98","first-page":"OT1","volume":"82","author":"GM Duarte","year":"2022","unstructured":"Duarte GM, Ara\u00fajo DC, Jales RM, et al. Abstract OT1-04-03: sentinel lymph node biopsy versus no axillary surgery in early breast cancer clinically and ultrasonographically node-negative: a multicentre prospective randomized controlled trial (VENUS trial). Cancer Res. 2022;82(4 Suppl):OT1-04.","journal-title":"Cancer Res."},{"key":"19672_CR99","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12885-017-3443-x","volume":"17","author":"LM Van Roozendaal","year":"2017","unstructured":"Van Roozendaal LM, Vane ML, Van Dalen T, et al. Clinically node-negative breast cancer patients undergoing breast-conserving therapy: sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013\u201308). BMC Cancer. 2017;17:459.","journal-title":"BMC Cancer."},{"key":"19672_CR100","doi-asserted-by":"crossref","unstructured":"Stanczyk M, ElSherif A, Cheung T, Fanning A, Mendiola A, Fenton A, et al. Axillary surgical management in breast cancer patients after neoadjuvant systemic therapy: a Delphi study. Breast Care. 2025;20(5):338-47","DOI":"10.1159\/000546267"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19672-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19672-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19672-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T04:01:43Z","timestamp":1786248103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19672-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19672"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19672-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Julie Lang reports serving on the speaker bureau for Merck, receiving a research grant from Flow Pharma, serving on the advisory board for Novartis, and serving as faculty speaker for OncLive. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}